AbbVie and Roche's Venclexta is a first-in-class BCL-2 inhibitor that made its debut in 2016 in the U.S. for the treatment of patients with relapsed chronic lymphocytic leukemia caused by a particular genetic mutation.
Gilead cancer drug Zydelig--flagged earlier this year after serious adverse events cropped up in studies--can stay on the market with some new recommendations, European regulators have concluded.
